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Abstract
Introduction: Anorexia nervosa (AN) is an eating disorder characterised with extremely low weight. Adipokines are adipose tissue-
derived substances that show a wide spectrum of biological activities. We aimed to assess selected adipokine levels in women with AN 
before and after nutritional intervention. We also sought to examine whether BMI is the only confounding factor influencing adipokine 
assessment in AN.
Material and methods: Sixty-five women participated in the study: 20 individuals with AN before any treatment, 18 AN patients after 
nutritional intervention lasting for at least six months, and 27 women as controls. In all participants blood collection and anthropometric 
measurements were performed. ELISA was used for evaluation of leptin receptor, adiponectin and its isoforms, and resistin. Leptin was 
assessed with RIA, and visfatin was measured with EIA assay. 
Results: Leptin and free leptin index (FLI) were lowest in treatment–naïve AN women. HMW-adiponectin and visfatin were enhanced 
in AN. Other adipokine levels showed no significant differences. When two subsets of anorexia nervosa were compared, only leptin, 
leptin receptor, and FLI were markedly different. When data were adjusted to BMI, leptin and FLI remained significantly different in the 
pre-treated AN subgroup when compared with the control group.
Conclusions: Our results suggest that leptin is the most important adipokine in AN. It is also important that in our AN population leptin 
and FLI are the only factors that are influenced not only by the fat content. (Endokrynol Pol 2017; 68 (4): 422–429)
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Streszczenie
Wstęp: Anorexia nervosa (AN) jest zaburzeniem odżywania i charakteryzuje się skrajnie niską masą ciała. Adipokiny to substancje wy-
dzielane przez tkankę tłuszczową o szerokim spektrum aktywności biologicznej.Celem pracy była ocena stężeń wybranych adipokin 
u kobiet z anorexia nervosa przed i po interwencji żywieniowej. Badano również czy wskaźnik masy ciała jest jedynym czynnikiem 
wpływającym na stężenia adipokin w AN.
Materiał i metody: Udział w badaniu wzięło 65 kobiet: 20 pacjentek z AN przed jakąkolwiek terapią, 18 pacjentek z AN po interwencji 
żywieniowej trwającej co najmniej 6 miesięcy, 27 kobiet z grupy kontrolnej. U wszystkich uczestniczek przeprowadzono pobranie krwi 
i badania antropometryczne. Metodą ELISA oznaczano receptor leptynowy, adiponektynę i jej frakcje oraz rezystynę. Leptyna była badana 
metodą RIA a wisfatyna z użyciem techniki EIA.
Wyniki: Stężenie leptyny oraz indeks wolnej leptyny były najniższe u pacjentek z AN przed leczeniem. Frakcja HMW adiponektyny oraz 
wisfatyna były podwyższone w przebiegu AN. Wartości pozostałych adipokin nie różniły się znacząco pomiędzy grupami. Porównując 
podgrupy z anorexia nervosa stwierdzono różnice jedynie w stężeniach leptyny i receptora leptynowego oraz indeksie wolnej leptyny. 
Dodatkowo po wyłączeniu wpływu BMI jedynie wartości leptyny i indeks wolnej leptyny pozostały znamiennie różne pomiędzy pa-
cjentkami z AN przed leczeniem a grupą kontrolną. 
Wniosek: Wyniki naszego badania sugerują, że najważniejszą adipokiną w AN jest leptyna. W naszej grupie pacjentek z AN leptyna 
i indeks wolnej leptyny były jedynymi czynnikami, których zmiany nie są wyłącznie zależne od zmian ilości tkanki tłuszczowej. 
(Endokrynol Pol 2017; 68 (4): 422–429)
Słowa kluczowe: leptyna; rozpuszczalny receptor leptynowy; indeks wolnej leptyny; adiponektyną; rezystyna; wisfatyna; anorexia nervosa
Introduction
Adipose tissue was traditionally considered as an en-
ergy reservoir; however, since the discovery of leptin 
it has been recognised as an endocrine organ. The en-
docrine activity of adipose tissue consists of the ability 
to produce and secrete biologically active substances 
termed adipokines, which maintain energy balance 
and control metabolism. 
Leptin, a peptide derived mostly from adipocytes, 
has receptors in different organs and tissues dispersed 
throughout the body. Leptin binds to six types of recep-
tor, but the soluble leptin receptor (sOB-R) has been re-
ported to be the main leptin binding protein. Moreover, 
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the ratio of serum leptin levels to sOB-R concentration, 
named free leptin index (FLI), corresponds with leptin 
action and determines leptin resistance [1, 2]. A wide 
spectrum of leptin receptor locations suggests pluri-
potent activity of this adipokine. Indeed, leptin influ-
ences metabolic processes, puberty, reproduction, and 
immunological processes. Specifically, it plays a role in 
maintaining body energy balance by central regulation 
of appetite. [2]. Another important adipokine, adiponec-
tin, is a 244-aminoacid peptide predominantly secreted 
by adipocytes. It circulates in the periphery in three 
forms that differ between each other in multimerisation 
and biological activity: low molecular weight trimer 
(LMW), medium molecular weight hexamer (MMW), 
high molecular weight multimer (HMW), and total 
adiponectin. Adiponectin reveals its activity by bind-
ing to two types of receptors, AdipoR1 and AdipoR2. It 
has been indicated that adiponectin possesses insulin-
sensitising, anti-atherogenic, and anti-inflammatory 
properties. Many studies revealed a significant negative 
correlation between adiponectin and body mass index 
seen in healthy individuals [2].
Resistin secreted by adipocytes and immunocom-
petent cells influences metabolic activity including 
insulin action. Resistin has also pro-inflammatory 
properties [3].
Visfatin produced and secreted by visceral adipose 
tissue appears to be a multifunctional protein, acting as 
a hormone, cytokine, and enzyme, which exerts insulin-
mimetic and adipogenic properties [2]. 
Changes in nutritional status and fat content may 
influence hormonal activity of adipose tissue. The 
majority of research has focused on obesity and its 
impact on the adipokine profile. Considerably fewer 
papers consider the adipokine pattern in chronic un-
dernutrition. 
Anorexia nervosa (AN) is an eating disorder char-
acterised by self-induced dietary restrictions leading 
to extremely low weight. A persistent decrease of fat 
amount results in hormonal disturbances, adipokine 
deregulation, and metabolic abnormalities. This disease 
is an important cause of physical and psychosocial 
morbidity [4]. Two types of anorexia nervosa are recog-
nised: restrictive (AN-R); and binge eating and purging 
type (AN-BP) [5]. In recent years a growing number 
of individuals suffering from anorexia nervosa has 
been observed [6, 7]. However, the incident rate varies 
between different populations [8]. To date, no genetic 
mechanisms underlying AN have been established [9]. 
Previous studies examined the interactions between 
anorexia nervosa and orexigenic and anorexigenic 
factors, as well as other peptides and hormones in the 
control of eating behaviour and energy metabolism in 
severe undernutrition [10–14]. Most papers focused on 
adipokine evaluation in malnourished AN individuals, 
without any assessment after long-term refeeding.
Due to the fact that an extremely low fat amount is 
typical for individuals suffering from AN, we decided 
to assess selected adipokine levels in AN women in the 
acute phase of the disease and after refeeding. We also 
aimed to examine whether BMI reflecting fat content is 
the only confounding factor of adipokine profile in AN.
Material and methods
The study group included thirty-eight women with 
diagnosed anorexia nervosa. All patients had restric-
tive subtype of AN. Depending on disease stage, indi-
viduals were divided into two different subgroups of 
patients. The first one included twenty women before 
any treatment, and the second group comprised an-
other eighteen patients after refeeding. The refeeding 
process lasted for at least six months and maximum of 
12 months. All the patients from the refeeding group 
underwent nutritional intervention only. No treat-
ment with antidepressants, anxiolytic or neuroleptic 
drugs, or with oestrogen or oestrogen combined with 
progesterone was conducted during the time of refeed-
ing. Clinical characteristics of the examined groups are 
presented in Table I.
All the participants with AN were recruited on a vol-
untary basis from the Endocrine Outpatient Clinic. The 
diagnosis of anorexia nervosa was based on the DSM IV.
Twenty-seven healthy women with normal BMI 
served as a control group. All the controls were vol-
unteers. None of the women among the controls had 
a history of eating disorders. 
Exclusion criteria were established, including en-
docrine diseases other than eating disorders. Smokers, 
alcohol abused individuals, and those receiving drugs 
were not included in the study.
Written, informed consent was obtained from all 
participants. The study was approved by the Bioethi-
cal Committee of the Centre of Postgraduate Medical 
Education, Warsaw, Poland and was in concordance 
with the Declaration of Helsinki.
All participants were examined on the day of blood 
collection, and anthropometric parameters were ob-
tained. Height was measured with use of a wall-mount-
ed ruler. Weight was assessed using a digital scale. Then, 
BMI was calculated according to the formula: weight 
(kg) divided by height squared (m2).
Blood samples were collected after at least eight 
hours of fasting. 
The probes containing EDTA and the protease 
inhibitor aprotinin were used. Blood was centrifuged 
at 1200 g for 10 minutes at 4°C to separate plasma. 
Plasma samples were aliquoted and subsequently 
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stored at –70°C until peptide determination assay was 
performed.
Plasma total adiponectin and isoforms of adiponec-
tin (HMW, MMW, and LMW) were measured using 
commercial ELISA kits (ALPCO Diagnostics, USA). The 
sensitivity of the assay was 0.50 ng/mL. Inter-assay and 
intra-assay CV were less than 5% and 10%, respectively.
Plasma leptin levels were determined with a com-
mercial RIA kit (Millipore, USA). Sensitivity of the leptin 
assay was 0.44 ng/mlL and inter-assay and intra-assay 
CV were 8.3% and 6.2%, respectively. 
sOB-R was measured using a commercially available 
ELISA test (BioVendor Laboratory Medicine, Czech 
Republic). The sensitivity of the leptin receptor assay 
was 0.4 ng/ml and inter-assay and intra-assay CV were 
9.81% and 7.23%, respectively.
FLI was calculated as the ratio of plasma leptin to 
sOB-R x 100. 
Plasma visfatin concentration was measured using 
EIA Kit (Phoenix Pharmaceuticals Inc., USA). Minimum 
detectable concentration was 2.3 ng/mL, and intra-
assay and inter-assay CV were less than 10% and 15%, 
respectively. 
Resistin was measured using an ELISA kit (Bio-
Vendor Laboratory Medicine, Czech Republic). The 
sensitivity of the assay was 0.012 ng/mL, and inter-assay 
and intra-assay CV were 8.1% and 6.6%, respectively.
All statistical analyses were performed using 
Statistica 10 (StatSoft Inc., USA). Data are presented 
as mean ± SD. The normality of distribution for all 
data was tested with Shapiro-Wilk test. Most of the 
results presented a lack of normal distribution. For 
evaluation of statistical significance between groups 
the Kruskall-Wallis rank test was used followed by 
Mann-Whitney U test. Significance of correlations be-
tween two variables was determined by the Spearman 
rank correlation coefficient. All p values less than 0.05 
were accepted as statistically significant. Data were 
adjusted to BMI.
Results
Data concerning clinical data and adipokine levels are 
presented in Table I.
Leptin concentrations in plasma were lowest in 
women with AN before treatment and significantly 
differed when compared with those of patients with 
AN after refeeding (3.02 ± 1.34 ng/mL vs. 7.36 ± 5.96 
ng/mL; p < 0.001) as well as with those of the controls 
(3.02 ± 1.34 ng/mL vs. 12.27 ± 7.92 ng/mL; p < 0.001)
In this study, we revealed that sOB-R was signifi-
cantly higher in AN individuals before treatment in 
comparison to AN patients after nutritional interven-
tion (30.44 ± 5.66 ng/mL vs.21.28 ± 6.23 ng/ml; p < 0.05). 
FLI, similarly to leptin values, was lowest in severely 
malnourished women, with significant differences seen 
when compared both to AN individuals after treatment 
and the control group (10.29 ± 5.20 vs. 41.59 ± 39.17; 
p < 0.001 and 10.29 ± 5.20 vs. 82.56 ± 88.92; p < 0.001, 
respectively). 
Total adiponectin and MMW, as well as LMW 
adiponectin, showed a non-significant tendency to be 
enhanced in patients with anorexia nervosa. Moreover, 
we observed a statistically important increase of HMW 
adiponectin in both subgroups of AN when compared 
to the controls (pre-treated AN group 3.52 ± 1.77 ug/ 
/mL vs. controls 2.77 ± 1.2 ng/mL; p < 0.01 and after 
treatment AN group 3.15 ± 1.85 ng/mL vs. controls 
2.77 ± 1.2 ng/ml; p < 0.01, respectively).
Obtained values of visfatin were markedly higher 
in both AN subsets than in the controls (pre-treated 
AN group 14.36 ± 4.11 ng/mL vs. controls 11.86 
± 4.6 ng/mL; p < 0.05 and after treatment AN group 
13.55 ± 3.60 ng/mL vs. controls 11.86 ± 4.6 ng/mL; 
p < 0.05, respectively). Furthermore, assessment of re-
sistin did not reveal any significant differences between 
all investigated groups. 
The results after adjustment to BMI are presented 
in Table I.
When results were adjusted to BMI, we observed 
that only leptin and FLI were markedly lower in the 
pre-treated AN subgroup when compared with the 
control group (p < 0.05 and p < 0.05, respectively). 
Furthermore, values of leptin and FLI were significantly 
lower in AN before treatment in comparison to those of 
AN after refeeding (p < 0.05 and p < 0.05, respectively).
The correlations are presented in Table II.
A number of significant correlations were identified 
in the study. In the whole group of anorexia nervosa, 
a positive correlation was seen between leptin and 
BMI (r = 0.65; p < 0.001) and a negative correlation 
was observed between leptin and leptin receptor 
(r = –0.34; p < 0.05). We also revealed that leptin recep-
tor positively correlated with total adiponectin, HMW, 
and MMW adiponectin (r = 0.38, p < 0.05; r = 0.34, 
p < 0.05; r = 0.47, p < 0.01, respectively). Moreover, 
FLI showed a positive correlation with BMI and 
a negative correlation with MMW adiponectin (r = 0.67, 
p < 0.001; r = –0.35, p < 0.05, respectively).
Discussion
The role of adipose tissue depots includes energy 
storage, endocrine and metabolic activity, as well as 
regulation of inflammatory action. Adipocytes are able 
to produce adipokines that act like classical hormones. 
Disturbed secretion of adipokines results in obesity, 
insulin resistance, and type 2 diabetes. On the other 
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hand, metabolic disorders may heighten dysregulation 
of adipokine secretion. Data concerning excessive fat 
amount and its correlation with adipokines have been 
widely discussed in the literature. However, despite 
a large body of literature suggesting the occurrence of 
a dysregulation in both central and peripheral modula-
tors of appetite in AN, there are limited but not conclu-
sive findings on the relationship between adipokines 
and eating disorders. The typical clinical feature of 
anorexia nervosa is loss of body fat. Although the total 
adipose tissue amount is decreased, this unquestionable 
fact does not always correspond with the disturbed 
adipokine profile that ought to be, at least theoretically, 
in opposition to the adipokine pattern seen in obese 
individuals. Presumably, levels of adipokines in AN 
should also differ in comparison with those of normal-
weight controls. In fact, our results did not confirm 
completely the above-mentioned hypothesis.
Leptin is the first discovered adipokine. It acts pe-
ripherally as well as in the central nervous system. It 
links nutritional status and activity of the brain on the 
hypothalamus level where hunger/satiety regulating 
sites are located. Moreover, leptin influences many other 
physiological processes [2]. Its secretion is stimulated by 
feeding and reduced by fasting as well as by negative 
energy balance.
In concordance with this general statement, in 
our group of patients with AN, we found that leptin 
levels were significantly lower than those found in 
the controls. In addition, a marked difference in leptin 
concentration was also observed between two subsets 
of AN patients with the lowest values demonstrated 
in untreated individuals. After adjustment to BMI the 
differences remained significant. 
Decreased leptin levels in acute phase of AN were 
consistently reported by other authors. A correlation 
between decreased BMI and low levels of leptin were 
also described in accessible literature [15–19]. 
Some researchers performed studies on the effect 
of weight gain in AN on leptin concentration. It was 
Table II. Correlations in the group of patients with anorexia 
nervosa
Tabela II. Korelacje w grupie pacjentek z anorexia nervosa
Parameter A Parameter B r p
BMI Leptin 0.65 < 0.001
BMI Leptin receptor –0.54 < 0.001
BMI Free leptin index 0.67 < 0.001
Total adiponectin Leptin receptor 0.38 < 0.05
HMW adiponectin Leptin receptor 0.34 < 0.05
MMW adiponectin Leptin receptor 0.47 < 0.01
Leptin Leptin receptor –0.34 < 0.05
Free leptin index MMW adiponectin –0.35 < 0.05
Table I. Clinical data and adipokine levels 
Tabela I. Dane kliniczne i stężenia adipokin
AN (AN1) 
Before treatment 
n = 20
AN (AN2) 
After treatment 
n = 18 
Control  
Group (C)  
n = 27
p p 
adjusted  
to BMI 
Age [years] 23.1 ± 8.24 24.23 ± 7.058 25.52 ± 5.81 NS —
BMI (kg/m2) 15.62 ± 1.13 18.57 ± 1.60 21.61 ± 2.08 a, b, c < 0.001 —
Total Adiponectin 
[ug/mL]
6.89 ± 2.62 6.60 ± 3.17 5.39 ± 1.91 NS NS
HMW adiponectin 
[ug/mL]
3.52 ± 1.77 3.15 ± 1.85 2.77 ± 1.20 a, b < 0.01 NS
MMW adiponectin 
[ug/mL]
2.16 ± 1.23 1.79 ± 0.85 1.71 ± 0.83 NS NS
LMW adiponectin 
[ug/mL]
1.22 ± 0.83 1.66 ± 1.11 1.41 ± 0.66 NS NS
Leptin 
[ng/mL]
3.02 ± 1.34 7.36 ± 5.96 12.27 ± 7.92 a, c < 0.001;  
b < 0.01
a, b, c < 0.05
Leptin receptor  
[ng/ml]
30.44 ± 5.66 21.28 ± 6.23 24.55 ± 10.70 c < 0.05 NS
Free leptin index (FLI) 10.29 ± 5.20 41.59 ± 39.17 82.56 ± 88.92 a, c < 0.001;  
b < 0.05
a, c < 0.05;  
b = 0.07
Resistin [ng/mL] 3.09 ± 1.16 3.77 ± 1.73 3.67 ± 1.10 NS NS
Visfatin [ng/ml] 14.36 ± 4.11 13.55 ± 3.60 11.86 ± 4.60 a, b < 0.05 NS
a — AN1 vs. C; b — AN2 vs. C; c — AN1 vs. AN2
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found that leptin may increase during fast refeeding, 
even to supra-physiological levels, in comparison with 
BMI-matched healthy controls [20, 21]. However, it was 
suggested that both plasma and cerebrospinal fluid 
levels of leptin after a long-term body mass recovery re-
store to similar concentrations as those seen in healthy, 
normal weight counterparts [22]. Interestingly, a recent 
study conducted by Baskaran et al. revealed that not 
only basal leptin levels are altered in AN but also se-
cretory dynamics of leptin were disturbed with mean 
pulse amplitude, mean pulse mass, and total pulsatile 
secretion being low in AN [23].
Our present findings of significant differences in 
leptin levels between AN individuals and the controls, 
which remained marked after adjustment to BMI, sug-
gest that it is not only the fat amount that has an impact 
on decreased leptin concentrations observed in the 
course of anorexia nervosa. Taking into account the fact 
that leptin during prolonged caloric deprivation may 
induce neuroendocrine changes, it could be speculated 
that dysfunctional hypothalamic activity during fasting 
might result in lowering of leptin concentration. 
In our study sOB-R was markedly decreased in the 
AN subpopulation after treatment when compared with 
naïve AN individuals and normal-weight controls. Ad-
ditionally, the highest values of sOB-R were observed 
in AN women before any treatment. Consequently, we 
assessed FLI and found that it was markedly decreased 
in individuals with AN in comparison with the controls, 
and the lowest values were seen in untreated patients. 
Similarly to leptin concentrations, these differences 
remained significant after adjustment to BMI. 
Research reports concerning sOB-R and FLI in AN 
patients are very limited. Data from the study by Mon-
teleone et al. are consistent with our findings. These 
authors observed in AN patients low concentrations 
of leptin and increased values of leptin receptor [19]. 
Our results also corroborate with those of the group of 
Misra, who reported a markedly reduced plasma leptin 
concentration coexisting with enhanced concentra-
tion of sOB-R and decreased FLI in AN participants in 
comparison with healthy adolescents [17]. Moreover, 
the study on a small group of adolescents with AN by 
Kratzsch et al. revealed that weight gain in patients with 
AN resulted in a significant increase in leptin concen-
tration, whereas the median sOB-R values decreased 
[24]. On the other hand, the group of Krizova reported 
that sOB-R was significantly enhanced in individuals 
with AN and remained unaffected by partial refeeding 
lasting for six weeks [25]. 
Based on our current findings and results of 
other authors who studied leptin, sOB, and FLI in 
AN, we can draw the conclusion that these factors 
might be affected by pathophysiological conditions 
accompanying AN not necessarily associated with 
changes in body fat storage. 
It is well established that circulating levels of 
adiponectin are inversely associated with BMI and 
intra-abdominal fat content [2]. Our data showed that 
the total adiponectin concentration was not markedly 
different between the groups under study. However, 
there was a non-significant tendency towards higher 
values of adiponectin in AN women independently 
of the disease phase when compared to the healthy 
controls. These results are in agreement with those 
reported by Nogueira et al. [26] and Amitani et al. [27]. 
Moreover, in another study conducted by the group 
of Iwahashi, individuals diagnosed with AN showed 
a tendency towards higher adiponectin levels than in 
the control group. These authors observed also a lack 
of correlation between adiponectin and BMI in these 
patients [28]. Furthermore, the group of Misra found 
that adiponectin levels did not differ in AN girls in com-
parison with healthy controls. There were no changes 
in adiponectin values even after weight gain. Interest-
ingly, in this population of girls with AN, adiponectin 
was not associated with BMI or fat content [29]. Bosy-
Westphal et al. reported no change in adiponectin levels 
after weight restoration [30]. However, other authors 
published contradictory data. The majority of research-
ers demonstrated that total adiponectin values were 
increased in AN individuals when compared with the 
controls [15, 18, 30–35]. On the contrary, a decrease in 
adiponectin concentration in severely malnourished 
AN patients was reported by Tagami et al. [36].
Data concerning correlation between total adiponec-
tin levels and weight are ambiguous. After adjustment 
for BMI we did not reveal any significant differences in 
adiponectin concentrations between the groups under 
study. These findings are in agreement with the results 
of the study by Misra et al., who failed to find any as-
sociated between adiponectin values and BMI in AN 
girls [29]. Moreover, Iwahashi et al. did not show any 
correlation between these parameters [28]. On the other 
hand, some authors found that enhanced adiponectin 
in AN individuals was related to lower adiposity [15, 
16, 18, 31]. In addition, Amitani et al. reported higher 
adiponectin concentration during the acute phase of 
disease in comparison with those of controls. They 
observed that these results were even enhanced when 
adiponectin levels were normalised for BMI [27].
In the literature, there are only a few reports on lon-
gitudinal changes in adiponectin concentration during 
refeeding therapy of AN patients. Generally, assessment 
of total adiponectin showed a bi-phasic pattern with 
a temporary increase in the levels of this adipokine 
observed at the beginning of treatment and a gradual 
decrease thereafter [18, 27, 33]. However, in the current 
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study we did not find significant differences between 
adiponectin levels when comparing AN individuals 
before and after refeeding. 
To our best knowledge, data concerning the pattern 
of adiponectin isoforms in AN are limited and equivocal. 
After analysing adiponectin fractions in AN in compari-
son with the controls, we found that only high molecular 
weight form was significantly higher in both subsets of 
AN. However, after adjustment to BMI these differences 
changed to non-significant. In addition, there were no 
differences between the two groups of AN. The group of 
Modan-Moses was the first to report an increased propor-
tion of HMW isoform in the malnourished phase of AN, 
followed by a decrease after weight gain to levels similar 
to control participants [33].Terra et al. also observed 
a marked increase in HMW adiponectin in AN [18]. These 
authors found as well that HMW adiponectin related 
negatively with disease duration after adjustment for 
age. Moreover, contrary to our findings, these researchers 
revealed that the weight restoration correlated positively 
with HMW adiponectin [18]. On the other hand, Amitani 
et al. failed to find any significant differences when com-
paring levels of all adiponectin forms of AN individuals 
and the controls [27]. However, these authors reported 
that the HMW ratio (HMW to total adiponectin) was 
significantly lower and the percentage of low-molecular-
weight (LMW) to total adiponectin (% LMW) was signifi-
cantly higher in the AN group compared with the control 
group. Also, they observed that the HMW ratio positively 
and the LMW ratio negatively correlated with BMI in the 
entire study population [27].
The underlying pathophysiological mechanisms 
that may be attributed to the above described discrep-
ancies in the assessment of total adiponectin and its 
fractions in AN subjects may result from diversified fat 
distribution in AN. We should be aware that BMI reports 
neither body composition nor the location of body fat. 
In fact, it has been reported that in the course of AN ado-
lescent females lose more central body fat, while adult 
females lose more peripheral fat. Moreover, it has also 
been established that partial weight restoration leads 
to greater fat mass deposition in the trunk region than 
other body regions in adolescent females. Furthermore, 
after short-term weight restoration, whether partial or 
complete, despite lean stature, adults show a central 
adiposity phenotype when compared to healthy age-
matched controls [37]. A temporary predominance of 
trunk fat depots in connection with biological activity 
of visceral adipose tissue may result in disturbed adi-
pokine secretion and activity, and consequently may 
predispose to insulin resistance, Generally, adiponectin 
concentration is closely and inversely related to insulin 
concentration and insulin resistance, and mirrors the 
whole body insulin sensitivity. 
Visfatin is mainly synthesised in abdominal adipose 
tissue. Although it influences glucose and insulin homeo-
stasis, the exact physiological role of visfatin is still not 
defined. Results from our recent research indicated that 
visfatin levels were markedly higher in AN individuals 
than in controls. The highest concentrations of visfatin 
were observed in naïve-to-treatment AN women. How-
ever, the results were not significantly different from 
those of a weight-recovered subset of patients. It is worth 
highlighting that after adjustment to BMI all differences 
were changed to non-significant. Data from the literature 
concerning visfatin levels in AN patients are limited and 
ambiguous. In one study, visfatin levels in the sera of 
teenage girls with AN were decreased when compared to 
the results of their healthy counterparts [38]. On the other 
hand, in another study no differences were observed 
between visfatin concentration in AN women and in 
normal-weight controls [39]. In the publication by Seidel 
et al. unchanged values of visfatin were also reported in 
AN individuals, both at the malnutrition stage and after 
gaining weight, when compared to the control group [40]. 
It is important to note that reported differences 
in visfatin levels in AN might be a result of the mu-
tual influence of different factors, including age of 
patients, body fat distribution, and metabolic activity 
of adipose cells. In fact, adipose tissue redistribution in 
the course of AN results in relative abdominal obesity 
with metabolic consequences that may include insulin 
resistance [37]. 
Resistin is a cytokine and it is synthesised by im-
munocompetent cells of fat tissue. Moreover, significant 
levels of resistin expression in humans were also found 
in mononuclear leukocytes, macrophages, spleen, and 
bone marrow cells. Besides, the relative abdominal 
adiposity observed in AN subjects might be associated 
with a state of low-grade chronic inflammation that 
could have an impact on resistin secretion.
In the present study we failed to find any significant 
differences in levels of resistin between the examined 
groups. Our findings are in line with the results of other 
authors. Terra et al. did not show any marked changes in 
values of resistin when comparing the results of AN in-
dividuals and a control group. The authors reported no 
correlations between concentration of resistin with dis-
ease duration and weight restoration [18]. In the study 
conducted by Nogueira et al. no significant difference in 
serum resistin values was seen in the whole AN group 
when compared with healthy control women [26]. 
Housova et al. did not reveal any differences in resistin 
concentration when comparing malnourished individu-
als with restrictive and the binge/purge subtype of AN 
with the controls [31]. On the contrary, the group of 
Dostalova reported that plasma resistin levels were 
significantly decreased in AN patients with restrictive 
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subtype of disease when compared to normal-weight 
controls [16, 41]. Notably, plasma resistin levels showed 
no significant correlation to the percentage of body fat 
and BMI [41]. Decreased levels of resistin in compari-
son to the controls were also observed in the study by 
Krizova et al. [32]. Dostalova et al. suggested that the 
observed low resistin levels in the course of AN were 
probably related to impaired mononuclear-macrophage 
number and/or function [16]. 
Our team presume that resistin secretion in AN 
might depend on the balance between pro-inflam-
matory factors and anti-inflammatory activity of the 
hypothalamic-pituitary-adrenal axis (HPA). In detail, 
on one hand, the state of low-grade chronic inflam-
mation induces production of cytokines, and on the 
other hand, central activation of the HPA axis in AN 
has been widely reported in the literature. The group 
of Schorr reported that cortisol measures demonstrated 
a U-shaped relationship with BMI. Furthermore, mean 
cortisol levels were higher in AN than in obese indi-
viduals [42]. Thus, a lack of balance between pro- and 
anti-inflammatory factors in individuals with AN may 
affect, among others, adipokine secretion.
We are aware that our study does have several 
limitations. A major limitation is the number of pa-
tients involved in the research protocol. However, we 
intended to have, as far as it was possible, a homogenic 
group of AN patients, to avoid confounding factors 
that could have a negative impact on the results. The 
second limitation is that only one outpatient unit was 
included for patient data collection. Thirdly, we did 
not assess a fat distribution pattern in our subjects with 
use of precise methods (e.g. DEXA). Instead, we based 
it on BMI, which is a universal, accessible, and no-cost 
parameter. Finally, we did not collected data concerning 
adipokine changes after short-term weight restoration, 
as was done by others. Therefore, as data concerning 
adipokine status in AN before and after refeeding re-
quire elaboration, further studies are needed.
Conclusions
Data from our study and findings of other authors 
show some discrepancies when considering levels of 
adipokines in the course of anorexia nervosa. Several 
factors may contribute to these differences, including 
the number of study participants, age, BMI and/or fat 
redistribution, concomitant diseases, and finally diver-
sity of laboratory techniques. 
Results from the current study suggest that leptin is 
the most important adipokine in AN. Notably, it is also 
important that in our AN study population leptin and 
FLI are the only factors that are influenced not only by 
the fat content. 
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